Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo

Scientific Reports

Volumn 5, Issue , 2015, Pages

  He, Xingxing ^a   Liu, Fang ^a   Yan, Jingjun ^a   Zhang, Yunan ^a   Yan, Junwei ^a   Shang, Haitao ^a   Dou, Qian ^a   Zhao, Qiu ^a   Song, Yuhu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLINE; MESSENGER RNA; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53;

ANIMAL; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DISEASE MODEL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; MUTATION; PATHOLOGY; PROTO ONCOGENE; TRANS SPLICING; XENOGRAFT;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE; CELL PROLIFERATION; CYCLINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MICE; MUTATION; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TRANS-SPLICING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84924105597     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08705     Document Type: Article

References (51)

1. Jemal, A. et al.Global cancer statistics. CA: a cancer journal for clinicians 61, 69-90 (2011).
2. Bruix, J.&Sherman, M. Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005).
3. Dragani, T. A. Risk of HCC: genetic heterogeneity and complex genetics. Journal of hepatology 52, 252-257 (2010).
4. de Lope, C. R., Tremosini, S., Forner, A., Reig, M.&Bruix, J. Management of HCC. Journal of hepatology 56 Suppl 1, S75-87 (2012).
5. Martin, J. & Dufour, J. F. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 14, 1720-1733 (2008).
6. Lozano, G. Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2, a001115 (2010).
7. Foulkes, W. D. p53-master and commander. NEngl J Med 357, 2539-2541 (2007).
8. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609-622 (2009).
9. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nature cell biology 15, 2-8 (2013).
10. Goh, A. M., Coffill, C. R. & Lane, D. P. The role of mutant p53 in human cancer. The Journal of pathology 223, 116-126 (2011).
11. Sell, S. Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res 63, 7553-7562 (2003).
12. Aravalli, R. N., Steer, C. J. & Cressman, E. N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 48, 2047-2063 (2008).
13. Liu, J. et al. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and metaanalysis. Eur J Cancer 48, 2328-2338 (2012).
14. Joerger, A. C. & Fersht, A. R. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26, 2226-2242 (2007).
15. Freed-Pastor, W. A. & Prives, C.Mutant p53: one name, many proteins. Genes & development 26, 1268-1286 (2012).
16. Bossi, G. & Sacchi, A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 29, 272-284 (2007).
17. Selivanova, G. & Wiman, K. G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26, 2243-2254 (2007).
18. Cheok, C. F., Verma, C. S., Baselga, J. & Lane, D. P. Translating p53 into the clinic. Nature reviews. Clinical oncology 8, 25-37 (2011).
19. Levesque, A. A. & Eastman, A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 28, 13-20 (2007).
20. Suzuki, K.&Matsubara, H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011, 978312 (2011).
21. Yang, Y. &Walsh, C. E. Spliceosome-mediated RNA trans-splicing. Mol Ther 12, 1006-1012 (2005).
22. Wood, M., Yin, H. & McClorey, G. Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3, e109 (2007).
23. Pergolizzi, R. G. & Crystal, R. G. Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing. C R Biol 327, 695-709 (2004).
24. O'Connor, T. P. & Crystal, R. G. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet 7, 261-276 (2006).
25. Yu, X., Vazquez, A., Levine, A. J. & Carpizo, D. R. Allele-specific p53 mutant reactivation. Cancer cell 21, 614-625 (2012).
26. Hainaut, P. & Wiman, K. G. 30 years and a long way into p53 research. Lancet Oncol 10, 913-919 (2009).
27. Lane, D. P., Cheok, C. F. & Lain, S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2, a001222 (2010).
28. Roth, J. A. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2, 985-991 (1996).
29. Guo, J. & Xin, H. Chinese gene therapy. Splicing out the West? Science 314, 1232-1235 (2006).
30. Shimada, H. et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer science 97, 554-561 (2006).
31. Poyurovsky, M. V. & Prives, C. Unleashing the power of p53: lessons from mice and men. Genes & development 20, 125-131 (2006).
32. Donehower, L. A. & Lozano, G. 20 years studying p53 functions in genetically engineered mice. Nature reviews. Cancer 9, 831-841 (2009).
33. Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53 (2002).
34. Bossi, G. et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 7, 1870-1879 (2008).
35. Zhu, H. B. et al. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World journal of surgical oncology 11, 22 (2013).
36. Bossi, G. et al. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25, 304-309 (2006).
37. Watanabe, T. & Sullenger, B. A. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci U S A 97, 8490-8494 (2000).
38. Shin, K. S., Sullenger, B. A. & Lee, S. W. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther 10, 365-372 (2004).
39. Mansfield, S. G. et al. Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther 7, 1885-1895 (2000).
40. Liu, X. et al. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 20, 47-52 (2002).
41. Chao, H. et al. Phenotype correction of hemophilia A mice by spliceosomemediated RNA trans-splicing. Nat Med 9, 1015-1019 (2003).
42. Tahara, M. et al. Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med 10, 835-841 (2004).
43. Khoury, M. P. & Bourdon, J. C. p53 Isoforms: An Intracellular Microprocessor? Genes & cancer 2, 453-465 (2011).
44. Garcia-Cao, I. et al. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. The EMBO journal 21, 6225-6235 (2002).
45. Maggi, L. B., Jr. et al. ARF tumor suppression in the nucleolus. Biochimica et biophysica acta 1842, 831-839 (2014).
46. Weber, J. D. et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes & development 14, 2358-2365 (2000).
47. Ito, T. et al. Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas. Journal of gastroenterology 39, 355-361 (2004).
48. Taniguchi, K., Yamada, T., Sasaki, Y. & Kato, K. Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. BMC cancer 10, 530 (2010).
49. He, X. X. et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 31, 3357-3369 (2012).
50. Wang, Z. et al. Embryonic liver fodrin involved in hepatic stellate cell activation and formation of regenerative nodule in liver cirrhosis. Journal of cellular and molecular medicine 16, 118-128 (2012).
51. Wang, Z. et al. beta-2 spectrin is involved in hepatocyte proliferation through the interaction of TGFbeta/Smad and PI3K/AKT signalling. Liver international 32, 1103-1111 (2012).